Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL685723 | 1.00 | CTSV (0.36) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL1351991 | 1.00 | CTSV (0.36) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL12847902 | 0.85 | CTSV (0.32) | CTSVCTSLCTSSCTSK | |
| SCHEMBL685114 | 0.84 | CTSV (0.34) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL28066407 | 0.84 | LMNA (0.31) | — | |
| SCHEMBL25457735 | 0.83 | CTSV (0.35) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL25457736 | 0.83 | CTSV (0.35) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL25457734 | 0.83 | CTSV (0.35) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL1697108 | 0.82 | CTSV (0.35) | CTSVCTSLCTSSCTSK | |
| SCHEMBL12501615 | 0.81 | CTSV (0.33) | CTSVCTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| EP-2709613-A2 | METHODS FOR TREATING HCV | Gilead Sciences, Inc. (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2654900-A1 | COMBINATIONS FOR TREATING HCV | Gilead Sciences, Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130273005-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273005-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273005-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013040492-A2 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012087596-A1 | COMBINATIONS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130243726-A1 | METHODS FOR TREATING HCV | HAVCR2, DHFR, HCCS | CTSV 435/4885CTSL 769/4885CTSS 748/4885 |
| US-10456414-B2 | Methods for treating HCV | HAVCR2, HCCS, LIPC | CTSV 134/4885CTSL 468/4885CTSS 466/4885 |
| US-20130273005-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CTSV 134/4885CTSL 468/4885CTSS 466/4885 |
| US-20170189439-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CTSV 134/4885CTSL 468/4885CTSS 466/4885 |
| US-20170042961-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CTSV 134/4885CTSL 468/4885CTSS 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.